NO.1 全球首个治疗药物成瘾的侵入式脑机接口产品在中国获批 12月15日，中国国家药品监督管理局签发了景昱医疗科技（苏州）股份有限公司侵入式脑机接口治疗药 物成瘾的三类产品注册证。这是全球首个获批用于治疗成瘾类精神疾病的侵入式脑机接口产品。该系统 对伏隔核和内囊前肢进行刺激，用于难治性的中重度阿片类药物成瘾患者的防复发辅助治疗。植入式脑 深部神经刺激系统填补了物理性干预阿片类药物成瘾治疗的技术空白，为阿片类药物成瘾患者的治疗提 供了更多选择。 点评：该产品获批具有里程碑意义，显示我国脑机接口产品在精神疾病治疗领域的应用走在全球前列。 但侵入式方案在安全性上仍需长期验证，商业表现亦有待观察。 NO.2 海思科子公司四款新药获批临床 12月16日，海思科公告称，子公司上海海思盛诺医药科技有限公司近日收到国家药品监督管理局下发的 《药物临床试验批准通知书》，同意开展HSK45019片、HSK50042片、注射用HSK55718、HSK36357 胶囊4款化学药品1类创新药的临床试验。 点评：短期内多款1类新药获批临床，体现海思科研发管线的广度。不过，创新药研发周期长、环节 多、风险高，容易受到一些不确定性因素的影 ...

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has signed an agreement with Peking University Health Science Center to establish the "Peking University Medicine - Sunshine Nuohuo Innovative Drug Joint Laboratory," focusing on cutting-edge fields such as cell therapy and gene therapy to develop clinical candidate drugs [1][2]. Group 1: Overview of Cooperation - The collaboration aims to enhance independent innovation capabilities and national core competitiveness, promoting quality improvement in innovative research and development [2]. - The partnership does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1]. Group 2: Basic Information of Partners - Peking University Health Science Center is the first western medical school established by the Chinese government and is part of the "211 Project," with a strong foundation in teaching, research, and medical education [3]. - There are no existing relationships of dishonesty or conflicts of interest between the partners [4]. Group 3: Main Content of the Cooperation Agreement - The agreement outlines that Peking University will organize research efforts, while Sunshine Nuohuo will provide funding and address technical challenges [5][6]. - The laboratory will focus on developing world-class clinical candidate drugs, including innovative therapies in cell and gene treatment [7][10]. Group 4: Funding and Management - Sunshine Nuohuo will provide a total of RMB 20 million (approximately 2 million) for the laboratory's operation, with an initial funding of RMB 10 million (approximately 1 million) to be transferred within 30 working days of the agreement [9]. - The intellectual property rights from the research conducted in the laboratory will be jointly owned by both parties, typically shared equally [9]. Group 5: Impact on the Company - This collaboration is a strategic move to deepen the company's innovation in drug development and enhance its core competitiveness, leveraging Peking University's research strengths and Sunshine Nuohuo's capabilities in drug development and commercialization [12]. - The funding for this partnership will come from the company's own resources, ensuring no adverse impact on cash flow or existing operations [12].

Group 1 - Action Education plans to repurchase shares worth between 20 million to 25 million yuan at a price not exceeding 45 yuan per share for employee stock ownership plans or equity incentives [1] - Fulin Technology's shareholders plan to reduce their holdings by up to 2% of the company's total shares, amounting to a maximum of 24.44 million shares starting from December 22, 2025 [2] - Huashu shares' shareholders intend to reduce their holdings by up to 1% of the company's total shares, which is a maximum of 35.94 million shares [3] Group 2 - Silan Microelectronics has obtained a filing certificate for its 12-inch high-end analog integrated circuit chip manufacturing production line project, with an investment of 10 billion yuan and a monthly production capacity of 20,000 wafers [4] - Aerospace Information confirms that its main business does not involve commercial aerospace and that its operations are normal without significant changes [5] - Qinglong Pipe Industry signed a supply contract worth 294 million yuan for PCCP and pressure steel pipes, accounting for 10.43% of its 2024 revenue [6] Group 3 - Huaxin Precision plans to invest up to 1 billion yuan of idle funds in low-risk financial products [7] - Hainan Rubber received insurance compensation totaling approximately 26.65 million yuan for rubber income and tree insurance [8] - Lianmei Holdings announced the suspension of its subsidiary Fulin Thermal Power due to economic slowdown and reduced customer demand [9] Group 4 - Ruifeng Bank has been approved to issue up to 2.5 billion yuan in secondary capital bonds to enhance its capital and risk resistance [11] - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for its life insurance subsidiary, totaling 250.32 billion yuan [12] - Sunshine Nuohuo signed an agreement with Peking University to establish a joint laboratory for innovative drug development [13] Group 5 - Century Huatong completed the cancellation of 56.12 million repurchased shares, reducing its total share capital from 7.428 billion to 7.372 billion shares [14] - Yaxin Security received a government subsidy of 3 million yuan [15] - Haili Biology's subsidiary received registration certification for a bone repair material in Indonesia [16] Group 6 - Yian Technology's subsidiary secured a major project for magnesium alloy components worth 430 million yuan, expected to start production by the end of March 2026 [17] - Jiangte Electric plans to contest the proposed cancellation of its lithium-containing mining rights [18] - COFCO Technology announced the resignation of its deputy general manager due to work changes [19] Group 7 - Fangsheng Pharmaceutical passed the GMP compliance inspection for its raw material production lines [21] - Bohai Ferry announced the resignation of two deputy general managers for personal and age-related reasons [22] - ST Fuhua appointed a new general manager [23] Group 8 - Huazhong CNC received project funding of 17.7 million yuan, accounting for 31.97% of its audited net profit for 2024 [24] - Oppein Home used 15 million yuan of idle funds to purchase a large time deposit with a 0.9% annual yield [25] - China General Nuclear Power's Ningde Unit 6 has begun full construction, utilizing Hualong One technology with a capacity of 1210 MW [26] Group 9 - Jiayuan Technology's chairman has had the investigation order lifted, and the company is operating normally [27] - Fulaixin Materials' application for a specific stock issuance has been approved by the Shanghai Stock Exchange [28] - Shuhua Sports plans to invest up to 500 million yuan in a health industry park project [29] Group 10 - Rhine Biology's stock will continue to be suspended due to ongoing control change and asset acquisition plans [30] - Haishi Science received approval for clinical trials for four innovative drugs targeting various diseases [31] - Hangcai Co. plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 80 yuan per share [32] Group 11 - Yinxin Technology received a cash dividend of 18 million yuan from its subsidiary [33] - Tianfulong plans to increase its wholly-owned subsidiary's capital by 580 million yuan [34] - Poly United's subsidiary won a bid for a stripping project worth 1.528 billion yuan [35] Group 12 - Minglida's deputy general manager resigned due to health reasons [36] - ST Guohua appointed a new deputy general manager [37] - China Xidian's subsidiaries won contracts totaling 1.005 billion yuan for Southern Power Grid projects [38]

北京阳光诺和药物研究股份有限公司 关于自愿披露共建联合实验室的公告 证券代码：688621 证券简称：阳光诺和 公告编号：2025-110 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次合作事项概述 为贯彻国家科技发展方针，提升自主创新能力与国家核心竞争力，促进双方 创新研发工作提质增效，公司与北京大学医学部合作共建"北大医学-阳光诺和 创新药物联合实验室"。双方将聚焦细胞治疗、基因治疗等前沿领域，以开发临 1 北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"或"公 司"）与北京大学医学部本着平等自愿、优势互补的原则签署《北京 大学医学部与北京阳光诺和药物研究股份有限公司共建"北大医学-阳 光诺和创新药物联合实验室"协议书》。双方将聚焦细胞治疗、基因 治疗等前沿领域，以开发临床候选药物为核心目标，充分发挥各自优 势，协同推进公司在创新药物研发领域的高质量发展。 本次合作不构成关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。 公司将根据合作具体事项的后续进展，按照相关法 ...

格隆汇12月16日丨阳光诺和(688621.SH)公布，为贯彻国家科技发展方针，提升自主创新能力与国家核 心竞争力，促进双方创新研发工作提质增效，公司与北京大学医学部合作共建"北大医学-阳光诺和创新 药物联合实验室"。双方将聚焦细胞治疗、基因治疗等前沿领域，以开发临床候选药物为核心目标，充 分发挥各自优势，协同推进公司在创新药物研发领域的高质量发展。 ...

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), has announced a collaboration with Peking University Health Science Center to establish the "Peking University Medicine - Sunlight Nuohe Innovative Drug Joint Laboratory" aimed at enhancing independent innovation capabilities and national core competitiveness [1] Group 1: Collaboration Details - The partnership will focus on cutting-edge fields such as cell therapy and gene therapy [1] - The primary goal is to develop clinical candidate drugs, leveraging the strengths of both parties to promote high-quality development in innovative drug research and development [1]

Core Viewpoint - The company, 阳光诺和, has announced a collaboration with Peking University Health Science Center to establish the "Peking University Medicine - 阳光诺和 Innovation Drug Joint Laboratory" aimed at enhancing independent innovation capabilities and national core competitiveness [1] Group 1: Collaboration Details - The partnership will focus on cutting-edge fields such as cell therapy and gene therapy [1] - The primary goal is to develop clinical candidate drugs, leveraging the strengths of both parties [1] - This initiative is part of the company's strategy to promote high-quality development in the field of innovative drug research and development [1]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [7] Core Insights - The medical and biological sector experienced a decline of 1.04% this week, ranking 17th among 31 primary industries [15] - The medical services sub-sector reported a closing value of 6239.94 points, with an increase of 1.67% [28] - The report highlights a shift in policy focus from cost control to quality and efficiency in the medical sector, emphasizing the need for innovation and sustainable practices [4][70] Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.74X, with a PB (lf) of 3.20X, showing a slight decrease from the previous week [3][36] - The top-performing companies in the medical services sector include Zhaoyan New Drug (+23.4%) and MediWest (+12.5%), while the underperformers include Guangzheng Eye Hospital (-9.4%) and Lanwei Medical (-8.7%) [2][34] Economic Policy Developments - The Central Economic Work Conference emphasized optimizing drug procurement and deepening medical insurance payment reforms, aiming to enhance the quality and efficiency of the medical industry [4][70] - The introduction of a long-term care insurance system is expected to stimulate the rehabilitation care industry and address aging population needs [11][72] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the weight-loss drug supply chain, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [13][74] - It also points to potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [13][75]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-109 北京阳光诺和药物研究股份有限公司 2025年第五次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （二） 股东会召开的地点：北京市昌平区科技园区双营西路 79 号院 29 号楼公 司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 39,293,486 | | 普通股股东所持有表决权数量 | 39,293,486 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.9573 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.9573 | （四） 表决方式是否符合《公司法》及公司章程的规定 ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年第五次临时股东会的法律意见 京天股字（2025）第 757 号 致：北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称公司）2025 年第五次临时股 东会（以下简称本次股东会）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 12 月 12 日 14:30 在北京市昌平区科技园区双营西路 79 号院 29 号楼公司会 议室召开。北京市天元律师事务所（以下简称本所）接受公司聘任，指派本所律师 参加本次股东会会议并对本次股东会进行见证，并根据《中华人民共和国公司法》 《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东会规则》（以 下简称《股东会规则》）以及《北京阳光诺和药物研究股份有限公司章程》（以下 简称《公司章程》）等有关规定，就本次股东会的召集、召开程序、出席现场会议 人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《北京阳光诺和药物研究股份有限公司第 二届董事会第二十七次会议决议公告》、《北京阳光诺和药物研究股份有限公司关 于召开 2 ...